These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

803 related items for PubMed ID: 19886227

  • 1. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 2. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 Oct; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 3. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M, Uder M.
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [Abstract] [Full Text] [Related]

  • 4. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M, Thuillier D, Lok C, Gras-Champel V.
    Therapie; 2007 Jun; 62(2):169-72. PubMed ID: 17582319
    [Abstract] [Full Text] [Related]

  • 5. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [Abstract] [Full Text] [Related]

  • 6. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent].
    van der Meij N, Keur I, van Lienden KP, Scheepstra CG, Bos JD.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2898-903. PubMed ID: 18257437
    [Abstract] [Full Text] [Related]

  • 7. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Dec 29; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 8. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS, Marckmann P.
    Eur J Radiol; 2008 May 29; 66(2):180-3. PubMed ID: 18342468
    [Abstract] [Full Text] [Related]

  • 9. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR.
    Eur J Radiol; 2008 May 01; 66(2):230-4. PubMed ID: 18372138
    [Abstract] [Full Text] [Related]

  • 11. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK.
    Eur J Radiol; 2008 May 01; 66(2):175-9. PubMed ID: 18343072
    [Abstract] [Full Text] [Related]

  • 12. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP, Cattanéo A, Saussereau E, Mahieu L, Guerbet M, Lacroix C.
    Ann Pharm Fr; 2009 Sep 01; 67(5):335-9. PubMed ID: 19695369
    [Abstract] [Full Text] [Related]

  • 13. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH.
    J Am Coll Radiol; 2008 Jan 01; 5(1):29-35. PubMed ID: 18180006
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
    Penfield JG, Reilly RF.
    Semin Dial; 2008 Jan 01; 21(2):129-34. PubMed ID: 18225999
    [Abstract] [Full Text] [Related]

  • 15. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan 01; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ, Kagan A, Chibnik LB, Kay J.
    Arthritis Rheum; 2007 Oct 01; 56(10):3433-41. PubMed ID: 17907148
    [Abstract] [Full Text] [Related]

  • 17. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Oct 01; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 18. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J, Snow T, Hiremagalur B.
    Nephrology (Carlton); 2008 Jun 01; 13(3):235-41. PubMed ID: 18221255
    [Abstract] [Full Text] [Related]

  • 19. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C.
    Toxicology; 2008 Jun 27; 248(2-3):77-88. PubMed ID: 18440117
    [Abstract] [Full Text] [Related]

  • 20. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM.
    Clin Exp Dermatol; 2007 Jul 27; 32(4):353-8. PubMed ID: 17433041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.